What effect does doubling the dose of clopidogrel have on outcomes in patients undergoing PCI? Dr. Salim Yusuf discusses the results of the CURRENT-OASIS 7 trial and other new data on antithrombotic agents.

Recently published data suggest that prior polyvascular disease increases the risk for inhospital adverse events in patients with ACS. Join Drs. Deepak Bhatt, Jean-Pierre Bassand, and José R. Gonzalez-Juanatey for a discussion of the current data on identification and management of patients with polyvascular disease.

AF can lead to stroke, congestive heart failure, and other serious complications. Successful management should include reducing these risks. Join our expert panel, Drs. Peter Rothwell, Donald Easton, and Mark Alberts, as they discuss new data and strategies for improving outcomes in patients with AF.

Despite modern therapy, the rates of death, MI, bleeding, and readmission remain high in patients with ACS. Join Drs. Jeffery Popma, Héctor Bueno, Freek Verheugt, and Sunil. Rao for a review of the latest data on antiplatelet therapy for patients with ACS.

Bleeding in ACS patients has been associated with increased adverse cardiac events and negative patient outcomes. Join Drs. Keith Fox, Gregg Stone, and Gabriel Steg as they discuss balancing the safety and efficacy of antithrombotic treatment options in ACS.

Atrial fibrillation (AF) is the most frequently occurring cardiac arrhythmia affecting some 2.2 million Americans with often serious clinical consequences.. Join Drs. Bhatt, Connolly and Camm for a discussion on the risk factors, management challenges, and new data on treatment options for patients with AF

Several recent studies have demonstrated that patients with atherothrombosis who experience bleeding may be at increased risk for long-term adverse ischemic events. Whereas the specific mechanism(s) that may explain the correlation between bleeding and ischemic events remains to be fully elucidated, these findings may have important ramifications for the selection of appropriate antiplatelet therapy. Drs. Berger, Mehta, Simon, Steg, and White discuss.

Harmonizing guideline recommendations for antiplatelet therapy with recent clinical trial data and concerns about bleeding can pose a challenge. Drs Berger, Mehta, Simon, Steg, and White each give presentations addressing issues relating to the appropriate use of antiplatelet therapy in patients with atherothrombotic disease

Warfarin remains the cornerstone of stroke prevention in patients with AF. However, many patients are unable or unwilling to take it. Could antiplatelet therapy fill this gap? How might investigational anticoagulants change the playing field? Dr Naccarelli leads a panel discussion with Drs Connolly and Camm.

Underdiagnosed and undertreated, PAD is a growing health and economic burden in an increasingly aging population. Routine screening and effective management strategies can reduce long-term adverse outcomes. Join Drs Bhatt, Steg, Hirsch, and Hiatt as they discuss treatment guidelines for prevention and treatment of PAD.

This program discusses the optimal use of combination antiplatelet therapy in non-ST elevation ACS, both in the acute and long-term setting. Additionally, the program will touch upon the early use of combination antiplatelet therapy in the setting of STEMI. Referencing the recent joint statement on DES by the Canadian Association of Interventional Cardiologists and the Canadian Cardiovascular Society, the program will also discuss optimal duration of dual antiplatelet therapy, strategies to prevent early discontinuation, and potential management strategies for patients who may require surgery while on dual antiplatelet therapy.